Literature DB >> 32138869

Antiretroviral Therapies for Human Immunodeficiency Virus and Liver Disease: Challenges and opportunities.

Julio C Abarca1, Leonor Huerta1, Nora A Fierro2.   

Abstract

The post antiretroviral therapy (ART) era for human immunodeficiency virus (HIV) infection resulted in a dramatically increased proportion of deaths attributed to liver-related causes in patients with HIV treated with ART. Additionally, as patients become older as a result of effective ART, liver-related conditions and application of safe therapies are now major concerns in the setting of HIV infection.
Copyright © 2020 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Coinfections; Liver fibrosis; Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Nucleoside reverse transcriptase inhibitors (NRTIs); Protease inhibitors (PIs)

Mesh：

Substances：

Year:  2020        PMID： 32138869     DOI： 10.1016/j.aohep.2020.02.004

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN： 1665-2681            Impact factor:   2.400


  1 in total

1.  Do contemporary antiretrovirals increase the risk of end-stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design.

Authors:  Jim Young; Vincent Lo Re; H Nina Kim; Timothy R Sterling; Keri N Althoff; Kelly A Gebo; M John Gill; Michael A Horberg; Angel M Mayor; Richard D Moore; Michael J Silverberg; Marina B Klein
Journal:  Pharmacoepidemiol Drug Saf       Date:  2021-11-23       Impact factor: 2.732
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.